BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...
BC Extra | Dec 2, 2019
Financial News

IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

IFM Therapeutics is doubling down on its asset-centric subsidiary model, raising $55.5 million to launch an incubator and up to three new subsidiaries focused on developing small molecules targeted at the innate immune system for...
BioCentury | Oct 1, 2019
Finance

STING start-up STipe first to emerge from Novo incubator

STipe, the first company out of Novo’s BioInnovation Initiative, raised €20 million ($21.9 million) in a series A round to develop technology designed to improve the therapeutic window of STING modulators in the clinic. Novo...
BC Extra | Sep 5, 2019
Company News

In third pharma deal, IFM partners cGAS-STING unit with Novartis

IFM Therapeutics' subsidiary model continues to pay off as the innate immune company scores its third high-value pharma deal in as many years. The biotech teamed up with Novartis Thursday in a collaboration and acquisition...
BC Innovations | Jun 4, 2019
Distillery Techniques

Tool compounds for probing the role of human cGAS in inflammatory diseases

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compound Small molecule inhibitors of human cGAS could be used to probe the role of cGAS-dependent signaling in inflammatory diseases. Screening of a compound library followed by optimization of the...
BC Innovations | Apr 12, 2019
Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
BC Extra | Mar 7, 2019
Preclinical News

STING structures reveal target sites

A trio of papers co-led by Zhijian “James” Chen revealed the molecular structure of STING in complex with two factors in its signaling pathway and a new function -- autophagy induction. The findings, reported in...
BC Extra | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...
BC Week In Review | Feb 13, 2019
Company News

IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor...
BC Extra | Feb 11, 2019
Company News

IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor...
Items per page:
1 - 10 of 26